Company: TAK
Filing Date: 2025-06-27
Form Type: 424B2
Source: 0001628280-25-033198
Chunk: 6

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-06-27
Form: 424B2
Chunk 6
---
target,” “will” and similar expressions in relation to us or our management to identify forward-looking statements. You can also identify forward-looking statements by discussions of strategy, plans or intentions. These statements reflect our current views with respect to future events and are subject to risks, uncertainties and assumptions, including the risk factors described in this prospectus supplement. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, our actual results may vary materially from those we currently anticipate.

Some of the risks inherent in forward-looking statements are identified in “Item 3. Key Information— D. Risk Factors” of Takeda’s most recent annual report on Form 20-F and in the “Risk Factors” section of this prospectus supplement. Other factors could also adversely affect Takeda’s results or the accuracy of forward-looking statements in this prospectus supplement, the accompanying prospectus or the documents incorporated by reference herein and therein, and you should not consider these to be a complete set of all potential risks or uncertainties.

The forward-looking statements included or incorporated by reference in this prospectus supplement and the accompanying prospectus are made only as of the dates on which such statements were made. The Issuer, the Guarantor and Takeda expressly disclaim any obligation or undertaking to release any update or revision to any forward-looking statement contained herein or therein to reflect any change in their expectations with regard thereto or any change in events, conditions or circumstances on which any statement is based.

<div align='center'>S-iv</div>

### PRESENTATION OF FINANCIAL AND OTHER INFORMATION
In this prospectus supplement, the term “Takeda” refers to Takeda Pharmaceutical Company Limited and, unless the context requires otherwise, its consolidated subsidiaries including TUSFI. The terms “TPC” and the “Guarantor” refers to Takeda Pharmaceutical Company Limited on a standalone basis as the guarantor of the Notes. The terms “TUSFI” and the “Issuer” refer to Takeda U.S. Financing, Inc. as the issuer of the Notes. The terms “we,” “us” and “our” refer to TPC (as the context requires, on a consolidated or standalone basis) and TUSFI collectively. We use the word “you” to refer to prospective investors in the Notes and the word “holder,” “Noteholder” or “Noteholders” to refer to the holders of the Notes.

Takeda’s consolidated financial statements are prepared on an annual